Telix Pharmaceuticals Ltd - Share Issue/Capital Change 2024

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Monday January 08, 2024

The +securities the subject of this notification are:

==> picture [8 x 9] intentionally omitted <==

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

		Total number of
ASX +security		+securities to be
code	Security description	issued/transferred	Issue date
TLXAP	SHARE RIGHTS	967,000	30/11/2023
TLXAO	SHARE APPRECIATION RIGHTS	1,335,630	30/11/2023

Refer to next page for full details of the announcement

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

1 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

==> picture [8 x 8] intentionally omitted <==

New announcement

1.5 Date of this announcement

8/1/2024

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

2 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

Part 2 - Issue details

==> picture [21 x 22] intentionally omitted <==

2.1 The +securities the subject of this notification are:

==> picture [8 x 8] intentionally omitted <==

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

==> picture [8 x 8] intentionally omitted <==

has an existing ASX security code ("existing class")

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

3 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description TLXAP : SHARE RIGHTS

Date the +securities the subject of this notification were issued 30/11/2023

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Equity Incentive Plan Rules accessible at www.telixpharma.com/investor-centre/corporate-governance

Any other information the entity wishes to provide about the +securities the subject of this notification

Share Rights granted to Telix employees. Material terms for Share Rights issued during 2023 are contained in the Company's 2022 Remuneration report, within its 2022 Annual Report accessible at https://telixpharma.com/investor-centr e/financial-reports-presentations/

Issue details

Number of +securities

967,000

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

Date the +securities the subject of this notification were issued

30/11/2023

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

4 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? No

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer to Telix's Equity Incentive Plan Rules accessible at www.telixpharma.com/investor-centre/corporate-governance

Any other information the entity wishes to provide about the +securities the subject of this notification

Performance Share Appreciation Rights (PSARs) granted to Telix employees. Performance metrics and material terms for PSARs issued during 2023 are contained in the Company's 2022 Remuneration report, within its 2022 Annual Report accessible at https://telixpharma.com/investor-centre/financial-reports-presentations/

Issue details

Number of +securities

1,335,630

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

5 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

	Total number of
ASX +security code and description	+securities on issue
TLX : ORDINARY FULLY PAID	323,726,683
4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)
	Total number of
ASX +security code and description	+securities on issue
TLXAJ : OPTION EXPIRING 30-JUN-2024 EX $1.83	88,000
TLXAI : OPTION EXPIRING 12-JAN-2024 EX $2.23	735,000
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	2,523,720
TLXAP : SHARE RIGHTS	1,277,000
TLXAO : SHARE APPRECIATION RIGHTS	8,600,537
TLXAH : OPTION EXPIRING 03-NOV-2023 EX $2.30	100,000
TLXAM : OPTION EXPIRING 20-JUL-2026 EX $5.37	584,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX $4.38	712,517

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

6 / 7

Notification of Issue, Conversion or Payment up of Unquoted Equity Securities

==> picture [21 x 22] intentionally omitted <==

Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1? Yes

5.1a Select the number of the applicable exception in Listing Rule 7.2

Notification of Issue, Conversion or Payment up of Unquoted E it S iti

7 / 7

AI assistant

Telix Pharmaceuticals Ltd Share Issue/Capital Change 2024

31324_rns_2024-01-07_692348aa-8534-4e41-9e11-4ed25d673fca.pdf

Entity name

Date of this announcement

The +securities the subject of this notification are:

Total number of +securities to be issued/transferred

1.1 Name of entity

1.2 Registered number type

Registration number

1.3 ASX issuer code

1.4 The announcement is

1.5 Date of this announcement

2.1 The +securities the subject of this notification are:

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

Any other information the entity wishes to provide about the +securities the subject of this notification

Number of +securities

ASX +security code and description

Date the +securities the subject of this notification were issued

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Any other information the entity wishes to provide about the +securities the subject of this notification

Number of +securities

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

AI assistant

Telix Pharmaceuticals Ltd — Share Issue/Capital Change 2024

31324_rns_2024-01-07_692348aa-8534-4e41-9e11-4ed25d673fca.pdf

Entity name

Date of this announcement

The +securities the subject of this notification are:

Total number of +securities to be issued/transferred

1.1 Name of entity

1.2 Registered number type

Registration number

1.3 ASX issuer code

1.4 The announcement is

1.5 Date of this announcement

2.1 The +securities the subject of this notification are:

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

Any other information the entity wishes to provide about the +securities the subject of this notification

Number of +securities

ASX +security code and description

Date the +securities the subject of this notification were issued

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class Yes

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Any other information the entity wishes to provide about the +securities the subject of this notification

Number of +securities

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

More from Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Ltd Share Issue/Capital Change 2024